Abstract Background There is preliminary evidence that individuals with previous SARS‐CoV‐2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE‐marked tests. This study aimed to close this gap. Methods Sixty‐nine seronegatives and 12 individuals post‐SARS‐CoV‐2 infection (tested by CE‐labelled Roche NC immunoassay or PCR‐confirmed assay) were included 21 ± 1 days after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. Antibody response to viral spike protein (S) was assessed by CE‐labelled Roche S and DiaSorin S1/S2 assays and by a surrogate virus neutralization test (sVNT). Results After a single dose of BNT162b2, individuals after natural SARS‐CoV‐2 infection presented with markedly higher anti‐S levels than naïve individuals (Roche S: 9078.5 BAU/mL [5267.0‐24 298.5] vs 79.6 [24.7‐142.3]; and DiaSorin S1/S2: 1465.0 AU/mL [631.0‐5365.0] vs 63.7 [47.8‐87.5]) and showed all the maximum observed inhibition activity in the sVNT (98%), without overlaps between groups. There was a trend for higher responses in those with a more distant infection, although not statistically significant. The relative antibody increase after dose 2 was significantly higher among naïve individuals (25‐fold), but antibody levels remained below that of seropositives. Conclusions Compared with naïve individuals, seropositives after natural SARS‐CoV‐2 infection presented with a substantially higher antibody response already after dose 1 of BNT162b2, as measured by two CE‐marked in vitro diagnostic tests and a sVNT. These results should stimulate discussion and research on whether individuals after previous SARS‐CoV‐2 infection would benefit from a two‐part vaccination schedule or whether these currently much‐needed second doses could be saved.
【저자키워드】 vaccination, serology, Antibody Response, SARS‐CoV‐2, seropositive, 【초록키워드】 BNT162b2 vaccine, antibody, Antibody Response, diagnostic test, Infection, in vitro, Spike protein, BNT162b2, immunoassay, Viral, diagnostic tests, virus neutralization test, response, neutralization test, Research, antibody levels, Roche, seronegative, surrogate virus neutralization test, single dose, Pfizer/BioNTech, Evidence, dose, viral spike protein, overlap, second dose, first dose, naïve individuals, individual, sVNT, DiaSorin, S1/S2, SARS‐CoV‐2 infection, assumption, preliminary evidence, inhibition activity, vaccination schedule, benefit, Result, tested, remained, receiving, supported, significantly higher, groups, statistically significant, stimulate, naïve individual, of BNT162b2,